Anesthetic and Analgesic Drug Products Advisory Committee Charter

Why It Matters

The committee’s expertise will shape FDA’s regulatory approach to opioid‑related products and novel analgesics, influencing market access and public‑health strategies amid the ongoing opioid crisis.

Key Takeaways

• Annual operating budget $126,950, staff cost $50,875.
• Committee advises FDA on analgesics, abuse‑deterrent opioids, anesthesiology.
• Six voting members, terms up to four years, two‑year charter life.
• Meetings open to public unless closed for legal reasons.
• Non‑federal members serve as Special Government Employees.

Pulse Analysis

The Anesthetic and Analgesic Drug Products Advisory Committee is a newly chartered FDA advisory body grounded in a suite of statutes ranging from the Federal Food, Drug, and Cosmetic Act to the Federal Advisory Committee Act. Its mandate is to synthesize the latest clinical and scientific evidence on analgesics, abuse‑deterrent opioids, and anesthetic agents, then convey nuanced risk‑benefit assessments to the Commissioner. By operating under a transparent, public‑meeting framework, the committee reinforces the agency’s commitment to openness while preserving the Commissioner’s ultimate decision‑making authority.

Operationally, the committee is modestly funded, with an annual budget of $126,950 that includes $50,875 for federal staff support, $8,473 in member fees, and $45,902 for travel reimbursements. The panel will consist of at least six voting members—selected for expertise in anesthesiology, pharmacology, epidemiology, and related fields—and may add non‑voting consumer or industry representatives as needed. Members serve terms of up to four years, and the charter itself expires after two years unless formally renewed, ensuring periodic review of its relevance and composition.

For pharmaceutical companies and public‑health advocates, the committee’s advisory opinions could materially affect product development pipelines, labeling decisions, and market entry strategies for new analgesics and opioid formulations. Its focus on abuse‑deterrent technologies aligns with broader governmental efforts to curb opioid misuse, while the open‑meeting policy offers stakeholders a venue to present data and viewpoints. Consequently, the committee serves as a strategic touchpoint where scientific insight meets regulatory policy, shaping the future landscape of pain management in the United States.